September 22, 2021
George Froehle, PA, a primary care clinician at CentraCare in rural St. Cloud, Minnesota, has been prescribing the HIV prevention pill tenofovir disoproxil fumarate plus emtracitabine […]
September 21, 2021
From testing to treatment, Global Fund HIV services have been hampered by COVID-19. “We’ve been set back by COVID but we’ve seen remarkable resilience, a lot […]
September 16, 2021
In August, when Assistant Secretary for Health Rachel Levine swore in eight new members to the President’s Advisory Council on HIV/AIDS (PACHA), the U.S.’s most influential […]
September 16, 2021
The Black women members of the President’s Advisory Council on HIV/AIDS (PACHA) are far from the first to bring their expertise to the HIV epidemic, as […]
September 3, 2021
Last year, Katherine Gill, MD, an HIV prevention researcher in Cape Town, South Africa, realized how jaded she’d become to vaccine research when the Pfizer COVID-19 […]
August 11, 2021
The future of preexposure prophylaxis (PrEP) is here, according to interim study results demonstrating the superiority of long-acting, injectable cabotegravir (CAB-LA) over the current workhorse, daily […]
August 3, 2021
“One of the most important considerations before switching HIV patients to injectable long-acting cabotegravir/rilpivirine [CAB/RPV LA; Cabenuva, ViiV Healthcare] is for the patient and the clinician […]
July 29, 2021
A single high dose of the antifungal agent liposomal amphotericin B (L-AmB; AmBisome, Gilead Sciences), with a background regimen of flucytosine and fluconazole, is noninferior and […]
July 28, 2021
A two-drug fixed-dose tablet therapy of dolutegravir/lamivudine (Dovato, ViiV Healthcare; DTG/3TC) shows noninferiority in viral suppression among people with HIV-1 who switch from any type of […]